{ "forecast_set_id": "SS-FVC-2026-10-BASELINE", "version": "1.0.0", "status": "published", "prepared_on": "2026-10-02", "issued_on": "2026-10-02", "evidence_cutoff": "2026-10-02", "horizon_start": "2026-10-03", "horizon_end": "2027-10-02", "canonical_path": "/ai-data-transactions/outlooks/frontier-value-capture/", "source_registry": { "ontology_version": "2.0.0", "data_rights_version": "1.0.17", "capability_catalog_version": "1.0.30", "canonical_record_count": 47, "construction_note": "18 legacy data-rights records plus 30 approved capability releases, with the Harell capability record merged into its linked legacy transaction, yield 47 canonical AI-access records.", "human_reviewed_record_count": 42, "provisional_legacy_record_count": 5, "strict_data_rights_record_count": 18, "capability_only_record_count": 29 }, "thesis": "Frontier-model economics will move beyond metered tokens and seats where AI creates economic value far larger than inference cost. The strongest opportunity is for frontier labs and domain incumbents to co-commercialize governed workflows and share downstream economics while the incumbent contributes scarce data, tools, validation, workflow control, and distribution.", "value_capture_stages": [ { "stage": 0, "name": "access_only", "definition": "Governed retrieval, data access, workflow access, or action execution with no separately disclosed AI-provider monetization structure." }, { "stage": 1, "name": "input_metered", "definition": "API, token, seat, training subscription, or license economics tied primarily to model/input access rather than downstream customer value." }, { "stage": 2, "name": "workflow_product", "definition": "A priced or co-developed AI workflow/service is commercialized, but disclosed economics are not tied to downstream revenue, milestones, royalties, savings, or outcomes." }, { "stage": 3, "name": "downstream_participation", "definition": "Disclosed economics participate in downstream commercialization or use through revenue share, sublicensing, transaction share, milestone, royalty, savings share, per-success fees, or another non-token mechanism." }, { "stage": 4, "name": "shared_product_economics", "definition": "A frontier model provider and domain incumbent jointly commercialize a product or service and both participate in disclosed downstream commercial revenue. Profit sharing is not required." } ], "anchor_observations": [ { "record_id": "SS-AIDT-2026-0016", "label": "OpenAI × Synopsys / GPT-Synopsys", "stage": 4, "reason": "OpenAI pays Synopsys a training subscription and the parties share downstream GPT-Synopsys revenue; exact economics are undisclosed.", "downstream_participation": true, "shared_product_economics": true }, { "record_id": "SS-AIDT-2026-0011", "label": "Harell Data governed training marketplace", "stage": 3, "reason": "Data owners receive a revenue share on training jobs executed against their datasets; this is an ecosystem precedent, not a frontier-lab partnership.", "downstream_participation": true, "shared_product_economics": false }, { "record_id": "SS-AIDT-2026-0014", "label": "OneMedNet real-world-data license", "stage": 3, "reason": "The arrangement includes recurring sublicensing revenue on downstream licenses; this is an ecosystem precedent, not a frontier-lab partnership.", "downstream_participation": true, "shared_product_economics": false } ], "forecasts": [ { "forecast_id": "SS-FVC-2026-001", "status": "unresolved", "scope": "New human-reviewed canonical AI Access records announced after the evidence cutoff and involving OpenAI, Anthropic, Google/DeepMind, Meta, xAI, or another provider operating frontier general-purpose models.", "thesis": "Non-token value capture becomes a repeatable frontier-lab business model rather than an isolated GPT-Synopsys structure.", "mechanism": "When model inference cost is small relative to measurable customer surplus, frontier labs have an incentive to exchange model capability and compute for participation in downstream economics instead of charging only for tokens or seats.", "confirmation": "By 2027-10-02, at least three new qualifying frontier-lab arrangements across at least two industries disclose Stage 3 or Stage 4 economics, and at least one reaches Stage 4.", "invalidation": "After a documented horizon-end search, fewer than three qualifying arrangements meet Stage 3 or Stage 4, or all disclosed frontier-lab arrangements remain Stage 0-2.", "confidence": "moderate", "confidence_rationale": "GPT-Synopsys is a strong Stage 4 anchor and the broader registry already contains multiple Stage 3 ecosystem precedents, but the sample contains only one clear frontier-lab shared-product structure.", "supporting_record_ids": [ "SS-AIDT-2026-0016", "SS-AIDT-2026-0011", "SS-AIDT-2026-0014" ], "outcome_observations": [], "issued_on": "2026-10-02", "horizon_start": "2026-10-03", "horizon_end": "2027-10-02" } ], "industry_predictions": [ { "prediction_id": "SS-FVC-IND-2026-001", "status": "unresolved", "issued_on": "2026-10-02", "horizon_start": "2026-10-03", "horizon_end": "2027-10-02", "industry_id": "engineering-design-simulation", "industry": "Semiconductor design, engineering simulation, and digital twins", "forecast": "This is the strongest near-term candidate for additional Stage 3-4 structures because economic outcomes are high value and unusually measurable through deterministic design, simulation, verification, and manufacturing constraints.", "confirmation": "At least one new Stage 3-4 frontier-lab arrangement beyond the existing OpenAI-Synopsys deal is announced in this industry during the horizon.", "invalidation": "No additional Stage 3-4 arrangement is found after a documented horizon-end sector search.", "confidence": "moderate_high", "candidate_set_is_not_partner_prediction": true, "candidate_companies": [ "Cadence Design Systems", "Synopsys / Ansys", "Siemens Digital Industries Software", "Dassault Systemes" ], "selection_basis": [ "scarce engineering workflow and tool control", "deterministic or physics-based validation", "high economic cost of design delay or failure", "deep enterprise distribution" ], "supporting_record_ids": [ "SS-AIDT-2026-0016", "SS-CAP-20260930-13C7C0BF7CA0" ], "outcome_observations": [] }, { "prediction_id": "SS-FVC-IND-2026-002", "status": "unresolved", "issued_on": "2026-10-02", "horizon_start": "2026-10-03", "horizon_end": "2027-10-02", "industry_id": "life-sciences-drug-discovery", "industry": "Drug discovery, biotechnology, and clinical-data science", "forecast": "Milestone, royalty, training-run, or shared-service economics should emerge because successful model outputs can influence high-value research decisions and the domain already contains separately monetized data rights.", "confirmation": "At least one new frontier-lab arrangement in this industry discloses Stage 3-4 economics during the horizon.", "invalidation": "New frontier-lab arrangements remain limited to licenses, seats, or access economics through the horizon.", "confidence": "moderate", "candidate_set_is_not_partner_prediction": true, "candidate_companies": [ "Tempus AI", "Recursion Pharmaceuticals", "Schrodinger", "IQVIA", "Thermo Fisher Scientific" ], "selection_basis": [ "scarce experimental or clinical data", "expensive research decisions", "measurable validation milestones", "existing licensing and co-development precedents" ], "supporting_record_ids": [ "SS-AIDT-2025-0001", "SS-AIDT-2025-0002", "SS-AIDT-2026-0012", "SS-CAP-20260926-73A63A01605C" ], "outcome_observations": [] }, { "prediction_id": "SS-FVC-IND-2026-003", "status": "unresolved", "issued_on": "2026-10-02", "horizon_start": "2026-10-03", "horizon_end": "2027-10-02", "industry_id": "cybersecurity", "industry": "Cybersecurity and managed defense", "forecast": "Outcome-linked structures should become viable where frontier models are embedded in live detection, validation, remediation, and re-testing loops, although liability will slow the move from workflow pricing to shared economics.", "confirmation": "At least one frontier-lab cyber arrangement discloses Stage 3-4 economics tied to managed defense, remediation, incident outcomes, or downstream service revenue.", "invalidation": "Frontier-lab cyber partnerships remain entirely Stage 0-2 through the horizon.", "confidence": "moderate", "candidate_set_is_not_partner_prediction": true, "candidate_companies": [ "Palo Alto Networks", "CrowdStrike", "Fortinet", "Cloudflare", "Microsoft Security" ], "selection_basis": [ "continuously refreshed proprietary threat data", "executable professional workflows", "measurable remediation outcomes", "large recurring enterprise spend" ], "supporting_record_ids": [ "SS-CAP-20260922-2BCDD20B8D7C", "SS-CAP-20260924-7D32DF2DC412" ], "outcome_observations": [] }, { "prediction_id": "SS-FVC-IND-2026-004", "status": "unresolved", "issued_on": "2026-10-02", "horizon_start": "2026-10-03", "horizon_end": "2027-10-02", "industry_id": "financial-professional-workflows", "industry": "Financial information, capital-markets infrastructure, legal, and professional workflows", "forecast": "Frontier labs should move from generic model access toward co-commercialized specialist workflow products, but regulated accountability and incumbent control make Stage 2 more likely before Stage 3-4 economics.", "confirmation": "At least two new frontier-lab specialist workflow arrangements are announced, with at least one disclosing Stage 3-4 economics.", "invalidation": "No new specialist frontier-lab workflow arrangement with downstream economics is found by horizon end.", "confidence": "moderate", "candidate_set_is_not_partner_prediction": true, "candidate_companies": [ "Bloomberg", "LSEG", "Nasdaq", "S&P Global", "FactSet", "Thomson Reuters", "RELX / LexisNexis" ], "selection_basis": [ "high-value proprietary information", "specialist workflow ownership", "entitlement and compliance infrastructure", "large professional customer bases" ], "supporting_record_ids": [ "SS-CAP-20260927-1111040F4978", "SS-CAP-20260929-538A8637DB46", "SS-CAP-20260929-92F337B317BB", "SS-CAP-20260930-39F057FD87F1" ], "outcome_observations": [] }, { "prediction_id": "SS-FVC-IND-2026-005", "status": "unresolved", "issued_on": "2026-10-02", "horizon_start": "2026-10-03", "horizon_end": "2027-10-02", "industry_id": "industrial-energy-operations", "industry": "Industrial operations, energy, equipment, and process optimization", "forecast": "The value-capture gap is structurally large because small improvements in uptime, yield, maintenance, or process design can be economically material, but fragmented systems and safety constraints will make observable deals slower to emerge.", "confirmation": "At least one new Stage 3-4 frontier-lab arrangement tied to industrial yield, maintenance, process optimization, or energy operations is announced during the horizon.", "invalidation": "No qualifying Stage 3-4 frontier-lab arrangement is found after a documented horizon-end sector search.", "confidence": "low_moderate", "candidate_set_is_not_partner_prediction": true, "candidate_companies": [ "Siemens", "Honeywell", "Rockwell Automation", "Caterpillar", "SLB", "Schneider Electric" ], "selection_basis": [ "high-cost operational outcomes", "renewable sensor and intervention histories", "control of executable industrial workflows", "strong customer distribution" ], "supporting_record_ids": [ "SS-AIDT-2026-0007", "SS-CAP-20260920-18759FE9B4C1" ], "outcome_observations": [] }, { "prediction_id": "SS-FVC-IND-2026-006", "status": "unresolved", "issued_on": "2026-10-02", "horizon_start": "2026-10-03", "horizon_end": "2027-10-02", "industry_id": "healthcare-operations", "industry": "Healthcare operations and clinical workflow", "forecast": "Frontier-model value capture should advance first through governed workflow products and later through outcome-linked economics because the economic surplus is large but reimbursement, safety, privacy, and clinical accountability make direct outcome sharing harder.", "confirmation": "At least two new frontier-lab healthcare workflow arrangements are announced and at least one moves beyond access or seat economics into Stage 3-4.", "invalidation": "No frontier-lab healthcare arrangement reaches Stage 3-4 during the horizon.", "confidence": "low_moderate", "candidate_set_is_not_partner_prediction": true, "candidate_companies": [ "Epic", "Oracle Health", "Cognizant TriZetto", "Optum", "athenahealth" ], "selection_basis": [ "large measurable administrative and clinical workflow cost", "deep proprietary longitudinal records", "embedded system-of-record distribution", "high regulatory and liability friction" ], "supporting_record_ids": [ "SS-CAP-20260930-06BC81AFAF68", "SS-CAP-20260930-B4467D37D033" ], "outcome_observations": [] } ], "secondary_watch": [ { "industry": "Commerce and payments", "candidate_companies": [ "Shopify", "PayPal", "Amazon", "Instacart", "Stripe" ], "note": "Transaction-share economics are structurally plausible and the registry already shows governed commerce and payment rails, but per-task economic surplus may be lower than engineering, life sciences, cyber, and industrial domains." } ], "update_protocol": { "cadence": "Reassess with each monthly market outlook and whenever a newly approved canonical record reaches Stage 3 or Stage 4.", "append_only": true, "rules": [ "Never rewrite an issued forecast to fit later evidence.", "Company candidate sets may be revised only in a dated successor version; prior lists remain preserved.", "A company appearing in a candidate set is not a prediction that it will sign a deal.", "Forecast outcomes must cite approved canonical record IDs and distinguish announcement date from discovery date.", "Undisclosed economics remain undisclosed; do not infer revenue share or outcome pricing from partnership language." ] }, "publication_review": { "status": "human_reviewed", "reviewer": "Mike Ye", "reviewed_on": "2026-10-02", "decision": "approve_and_publish", "approval_channel": "owner_conversation", "approval_record": "editorial/frontier-value-capture/approvals/2026-10-02-owner.json", "reviewed_pr": 33, "reviewed_head_sha": "be1797b8d18d34d3b2cf5700d88dc2966d8ce8ca", "approval_evidence": "Approved. 🫶♾️" }, "baseline_measures": { "frontier_stage_4_count": 1, "frontier_stage_3_or_4_count": 1, "broader_ecosystem_stage_3_or_4_anchor_count": 3, "note": "Stage counts are Strategic Signal analytical classifications for the named anchors, not a claim that every one of the 47 registry records has fully disclosed economics." } }